The 20 Key Moments in the 340B Program's 30-Year History
Omnicell
JANUARY 10, 2023
In a manual for hemophilia treatment centers, the agency states it is concerned that providers would have no reason to participate in 340B if insurers take the benefit of 340B savings from them. Four of the five staffers originally involved in the investigation now work for or lobby for the pharmaceutical industry.
Let's personalize your content